Dietary, Herbal
Dietary SupplementViscous fibre blend and Salba and American and Korean Red Ginseng capsules
NCT Number: NCT02553382
Despite the availability of multiple medications for the treatment of Type 2 diabetes, patients often continue to have difficulty attaining blood glucose targets and managing cardiovascular disease risk factors. Recent trends in non-pharmacological therapy have created a growing public interest in dietary supplements.
Research by this group and others support the benefits of whole grains, viscous dietary fibre and ginseng in the management of diabetes. The current study investigates whether the co-administration of a viscous dietary fibre blend, Salba (a grain rich in omega-3 fatty acids), and 2 varieties of ginseng roots will further improve blood sugar control and cardiovascular disease risk outcomes in individuals with Type 2 diabetes already receiving conventional treatments.
Patients with Type 2 diabetes receiving the recommended intervention in accordance with the Canadian Diabetes Association guidelines will be enrolled in a 6-month clinical study. Half of the participants will be randomly assigned to a 4-component intervention that comprises the co-administration of these four dietary/herbal supplements in addition to their usual treatment regimen; the other half will continue their usual treatment regimen in addition to taking high-oat fiber and wheat bran supplements.
The investigators hypothesize that an intensified, multi-targeted intervention with the addition of these dietary and herb components will further improve long-term blood glucose control and cardiovascular disease risk factors beyond conventional therapy. If this combination of viscous fiber, Salba and ginseng is shown to be beneficial, these remedies could complement current conventional therapy for Type 2 diabetes with the goal to further improve health outcomes.
Looking for future studies?
Notify Me40 year–75 year
All sexes
Interventional
Not applicable
St. Michael's Hopsital, Toronto, Ontario, Canada
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
Oat bran blend and wheat bran capsules
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Time frame: Baseline to 24 weeks
Assessed via analysis
Time frame: Baseline to 24 weeks
Assessed via analysis
Time frame: Baseline to 24 weeks
Assessed via analysis
Time frame: Baseline to 24 weeks
Assessed via analysis
Time frame: Baseline to 24 weeks
Assessed via analysis
Time frame: Baseline to 24 weeks
Assessed via analysis
Time frame: Baseline to 24 weeks
Assessed via laboratory analysis
Unity Health Toronto
Other
Co-administration of Three Complimentary Therapies (Viscous Dietary Fiber, Whole Grain and Ginseng) for Comprehensive Risk Reduction in Type 2 Diabetes Mellitus
Acronym: FIGHT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT06649344
Diabetes Mellitus, Diabetes Mellitus, Type 2
Tianjin, Tianjin Municipality, China
View Trial DetailsNCT07732218
Diabetes Mellitus, Diabetes Mellitus, Type 2
Peshawar, Khyber Pakhtunkhwa, Pakistan
View Trial DetailsNCT05351359
Diabetes Mellitus, Diabetes Mellitus, Type 2
Prague, Czechia
View Trial Details